About
The Long-Acting Technologies Community Advisory Board is a new cross-disease long-acting technologies (LAT) community advisory board (CAB) focused on malaria, the hepatitis C virus (HCV), and latent TB infection (LTBI) for a 4-year tenure, 2021-2024.
The LAT CAB reviews the state of treatment research, contributes to research protocols including those related to product acceptability, and engages in the research and development (R&D) process, including advising on research questions and trial design for long-acting technologies for malaria, HCV, and LTBI.
Meet the LAT CAB community experts.